SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Ann Oncol. 2012;23(8):2065-2071.

Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy.

, , , , , , , , , , , ,

제1저자 김남주 · 교신저자 이근욱

PMID 22589332 DOI 10.1093/annonc/mds106 IF 80.4 혈액종양내과
소속 (9)
  1. Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam.
  2. Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul.
  3. Department of Surgery.
  4. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul.
  5. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam.
  6. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul.
  7. Department of Ophthalmology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul.
  8. Department of Ophthalmology, Hallym University Sacred Heart Hospital, Anyang, Korea.
  9. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam. Electronic address: hmodoctor@hanmail.net.

Abstract

BACKGROUND This study was conducted to determine the incidence and clinical characteristics of lacrimal drainage obstruction (LDO) in patients receiving S-1 chemotherapy.

PATIENTS AND METHODS Consecutive 170 patients with gastric cancer who underwent curative surgery and received adjuvant S-1 chemotherapy were enrolled. S-1 was administered orally (40 mg/m2 b.i.d. on days 1-28 every 6 weeks) for 1 year. Ophthalmologic examinations were carried out on patients complaining of epiphora.

RESULTS Thirty-one patients (18%) developed epiphora. Among 31 patients, 25 underwent ophthalmologic examinations and 22 (88%) were diagnosed with LDO. The median time to the onset of LDO was 2.9 months. The most common site of obstruction was the nasolacrimal duct [86% (19/22)]; punctal [23% (5/22)] and canalicular obstruction [14% (3/22)] were also noted. In multivariate analysis, total gastrectomy [versus partial gastrectomy: hazard ratio (HR), 2.9; P=0.014] and creatinine clearance<50 ml/min (versus ≥50 ml/min: HR, 2.9; P=0.038) were independent risk factors for the development of LDO.

CONCLUSION Considering the high incidence of LDO in patients receiving S-1 chemotherapy, oncologists should be alert to epiphora and cooperate with ophthalmologists in the early stages to improve the quality of life of patients and avoid more complicated ophthalmologic procedures.

그 밖의 정보
출판 형태
Journal Article
저널
Annals of oncology : official journal of the European Society for Medical Oncology · eISSN 1569-8041
전자 출판
2012-05-15
MeSH
Adult · Aged · Antimetabolites, Antineoplastic / administration & dosage / adverse effects · Antineoplastic Combined Chemotherapy Protocols / administration & dosage / adverse effects · Drug Combinations · Female · Humans · Lacrimal Duct Obstruction / chemically induced / pathology · Male · Middle Aged · Nasolacrimal Duct / drug effects / pathology · Oxonic Acid / administration & dosage / adverse effects · Stomach Neoplasms / drug therapy / surgery · Tegafur / administration & dosage / adverse effects
Substances
Antimetabolites, Antineoplastic · Drug Combinations · S 1 (combination) · Tegafur · Oxonic Acid